Investigator Sponsored Studies, grants and sponsorships
Vertex Pharmaceuticals offers grants supporting independent research and innovation in cystic fibrosis, rare diseases, and related therapeutic areas to advance science and patient care.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (most programs, including ISS, grants, and sponsorships) | 2026 (next cycle for Circle of Care, RIA, and VIA awards)
Funding Amounts: No formal cap for most grants; CF Research Innovation Awards: up to $750,000 (3 yrs, independent) or $125,000 (2 yrs, mentored); VIA: up to $750,000/project; typical funding based on fair market value and program scope.
Summary: Supports independent research, education, and advocacy initiatives in cystic fibrosis, rare diseases, and Vertex's therapeutic areas through grants, sponsorships, and competitive awards.
Key Information: Most opportunities accept applications on a rolling basis; some competitive awards reopen in 2026.
Description
Vertex Pharmaceuticals offers a broad suite of funding opportunities for independent research, medical education, patient advocacy, and organizational sponsorships, primarily focused on cystic fibrosis, rare diseases, and other serious conditions within its research portfolio. Funding mechanisms include Investigator Sponsored Studies (ISS), grants for medical and patient education, advocacy initiatives, sponsorships, and competitive award programs such as the Circle of Care, Research Innovation Awards (RIA), and Vertex Innovation Awards (VIA). These programs are designed to foster scientific advancement, improve patient care, and support community engagement in areas aligned with Vertex’s therapeutic interests.
